Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for rare blood cancer

NCT ID NCT04624906

First seen Feb 04, 2026 · Last updated Apr 30, 2026 · Updated 8 times

Summary

This study tests a new drug, acalabrutinib, added to standard chemotherapy for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the combination for up to a year. The goal is to see if this approach improves response rates and controls the disease better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU de Quebec - University Laval

    Laval, Quebec, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Hamilton Health Sciences Centre - Juravinksi

    Hamilton, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

Conditions

Explore the condition pages connected to this study.